Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System
Abstract Introduction Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of t...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-12-01
|
| Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| Subjects: | |
| Online Access: | https://doi.org/10.1016/j.dadm.2019.01.011 |
| _version_ | 1818498156814401536 |
|---|---|
| author | Thilo vanEimeren Angelo Antonini Daniela Berg Nico Bohnen Roberto Ceravolo Alexander Drzezga Günter U. Höglinger Makoto Higuchi Stephane Lehericy Simon Lewis Oury Monchi Peter Nestor Matej Ondrus Nicola Pavese María Cecilia Peralta Paola Piccini José Ángel Pineda‐Pardo Irena Rektorová María Rodríguez‐Oroz Axel Rominger Klaus Seppi A. Jon Stoessl Alessandro Tessitore Stephane Thobois Valtteri Kaasinen Gregor Wenning Hartwig R. Siebner Antonio P. Strafella James B. Rowe MDS Neuroimaging Study Group and the JPND Working Group ASAP‐SynTau |
| author_facet | Thilo vanEimeren Angelo Antonini Daniela Berg Nico Bohnen Roberto Ceravolo Alexander Drzezga Günter U. Höglinger Makoto Higuchi Stephane Lehericy Simon Lewis Oury Monchi Peter Nestor Matej Ondrus Nicola Pavese María Cecilia Peralta Paola Piccini José Ángel Pineda‐Pardo Irena Rektorová María Rodríguez‐Oroz Axel Rominger Klaus Seppi A. Jon Stoessl Alessandro Tessitore Stephane Thobois Valtteri Kaasinen Gregor Wenning Hartwig R. Siebner Antonio P. Strafella James B. Rowe MDS Neuroimaging Study Group and the JPND Working Group ASAP‐SynTau |
| author_sort | Thilo vanEimeren |
| collection | DOAJ |
| description | Abstract Introduction Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders. Methods To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies. Results As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention‐to‐treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression). Discussion We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well‐defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials. |
| first_indexed | 2024-12-10T18:54:29Z |
| format | Article |
| id | doaj.art-83200e5382d4469d880f974cffe591af |
| institution | Directory Open Access Journal |
| issn | 2352-8729 |
| language | English |
| last_indexed | 2024-12-10T18:54:29Z |
| publishDate | 2019-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| spelling | doaj.art-83200e5382d4469d880f974cffe591af2022-12-22T01:37:13ZengWileyAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring2352-87292019-12-0111130130910.1016/j.dadm.2019.01.011Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility SystemThilo vanEimeren0Angelo Antonini1Daniela Berg2Nico Bohnen3Roberto Ceravolo4Alexander Drzezga5Günter U. Höglinger6Makoto Higuchi7Stephane Lehericy8Simon Lewis9Oury Monchi10Peter Nestor11Matej Ondrus12Nicola Pavese13María Cecilia Peralta14Paola Piccini15José Ángel Pineda‐Pardo16Irena Rektorová17María Rodríguez‐Oroz18Axel Rominger19Klaus Seppi20A. Jon Stoessl21Alessandro Tessitore22Stephane Thobois23Valtteri Kaasinen24Gregor Wenning25Hartwig R. Siebner26Antonio P. Strafella27James B. Rowe28MDS Neuroimaging Study Group and the JPND Working Group ASAP‐SynTau29Multimodal NeuroimagingDepartment of Nuclear MedicineMedical Faculty and University Hospital, University of CologneCologneGermanyDepartment of NeuroscienceUniversity of PaduaPaduaItalyDepartment of Neurology, UKSH, Campus KielChristian‐Albrechts‐UniversityKielGermanyDivision of Nuclear Medicine, Department of RadiologyUniversity of Michigan, and VAMCAnn ArborMIUSADepartment of Clinical and Experimental MedicineUniversity of PisaPisaItalyMultimodal NeuroimagingDepartment of Nuclear MedicineMedical Faculty and University Hospital, University of CologneCologneGermanyGerman Centre for Neurodegenerative Diseases (DZNE), and Technical University MunichDepartment of NeurologyMunichGermanyNational Institutes for Quantum and Radiological Science and TechnologyChibaJapanInstitut du Cerveau et de la Moelle épinière – ICM, Centre de NeuroImagerie de Recherche – CENIR, ICM Team “Movement Investigations and Therapeutics”, Sorbonne Universités, Inserm U1127, CNRS UMRParisFranceBrain & Mind Centre, Sydney Medical School, University of SydneySydneyNSWAustraliaDepartment of Clinical NeurosciencesHotchkiss Brain Institute, University of CalgaryCalgaryAlbertaCanadaQueensland Brain Institute, University of QueenslandBrisbaneQLDAustraliaAXON Neuroscience CRM Services SEBratislavaSlovak RepublicNewcastle Magnetic Resonance Centre & Positron Emission Tomography Centre, Newcastle UniversityNewcastle upon TyneUnited KingdomCenter for Medical Education and Clinical ResearchSection of NeurologyBuenos AiresArgentinaDepartment of MedicineImperial College LondonLondonUnited KingdomhmCINAC, University Hospital HM Puerta del Sur, CEU‐San Pablo UniversityMóstolesMadridSpainFirst Department of Neurology – Faculty of Medicine and CEITEC MUMasaryk UniversityBrnoCzech RepublicDepartment of NeurologyClinica Universidad de NavarraPamplonaSpainDepartment of Nuclear Medicine, InselspitalUniversitätsspital BernBernSwitzerlandDepartment of NeurologyMedical University of InnsbruckInnsbruckAustriaPacific Parkinson's Research Centre, University of British ColumbiaVancouverCanadaDepartment of Medical, Surgery, Neurological, Metabolic and Aging SciencesUniversity of Campania“L. Vanvitelli”Caserta CEItalyUniversité de Lyon, Université Claude Bernard Lyon 1Faculté de Medecine Lyon Sud Charles MerieuxLyonFranceDepartment of NeurologyUniversity of TurkuTurkuFinlandDivision of Clinical Neurology, Department of NeurologyMedical University of InnsbruckInnsbruckAustriaDanish Research Centre for Magnetic Resonance, Copenhagen University Hospital HvidovreHvidovreDenmarkE.J. Safra Parkinson Disease Program, Toronto Western Hospital & Krembil Research Institute, UHNTorontoOntarioCanadaDepartment of Clinical NeurosciencesUniversity of CambridgeCambridgeUnited KingdomMultimodal NeuroimagingDepartment of Nuclear MedicineMedical Faculty and University Hospital, University of CologneCologneGermanyAbstract Introduction Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders. Methods To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies. Results As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention‐to‐treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression). Discussion We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well‐defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.https://doi.org/10.1016/j.dadm.2019.01.011BiomarkerTrialsPSPMSACBDCBS |
| spellingShingle | Thilo vanEimeren Angelo Antonini Daniela Berg Nico Bohnen Roberto Ceravolo Alexander Drzezga Günter U. Höglinger Makoto Higuchi Stephane Lehericy Simon Lewis Oury Monchi Peter Nestor Matej Ondrus Nicola Pavese María Cecilia Peralta Paola Piccini José Ángel Pineda‐Pardo Irena Rektorová María Rodríguez‐Oroz Axel Rominger Klaus Seppi A. Jon Stoessl Alessandro Tessitore Stephane Thobois Valtteri Kaasinen Gregor Wenning Hartwig R. Siebner Antonio P. Strafella James B. Rowe MDS Neuroimaging Study Group and the JPND Working Group ASAP‐SynTau Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring Biomarker Trials PSP MSA CBD CBS |
| title | Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System |
| title_full | Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System |
| title_fullStr | Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System |
| title_full_unstemmed | Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System |
| title_short | Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System |
| title_sort | neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders proposal for a neuroimaging biomarker utility system |
| topic | Biomarker Trials PSP MSA CBD CBS |
| url | https://doi.org/10.1016/j.dadm.2019.01.011 |
| work_keys_str_mv | AT thilovaneimeren neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT angeloantonini neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT danielaberg neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT nicobohnen neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT robertoceravolo neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT alexanderdrzezga neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT gunteruhoglinger neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT makotohiguchi neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT stephanelehericy neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT simonlewis neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT ourymonchi neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT peternestor neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT matejondrus neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT nicolapavese neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT mariaceciliaperalta neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT paolapiccini neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT joseangelpinedapardo neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT irenarektorova neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT mariarodriguezoroz neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT axelrominger neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT klausseppi neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT ajonstoessl neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT alessandrotessitore neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT stephanethobois neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT valtterikaasinen neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT gregorwenning neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT hartwigrsiebner neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT antoniopstrafella neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT jamesbrowe neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem AT mdsneuroimagingstudygroupandthejpndworkinggroupasapsyntau neuroimagingbiomarkersforclinicaltrialsinatypicalparkinsoniandisordersproposalforaneuroimagingbiomarkerutilitysystem |